Pharmacokinetics of risperidone in different application forms - Comparing long-acting injectable and oral formulations.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  European Neuropsychopharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.euroneuro.2017.11.009PMID 29153926
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical response in a risperidone-medicated naturalistic sample: patients’ characteristics and dose-dependent pharmacokinetic patterns

  2017cited by this paper
• A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone

  2017cited by this paper
• Effect of smoking on risperidone pharmacokinetics - A multifactorial approach to better predict the influence on drug metabolism.

  2017cited by this paper
• Pharmacokinetic patterns of risperidone-associated adverse drug reactions

  2016cited by this paper
• Pharmacokinetic Drug-Drug Interactions of Mood Stabilizers and Risperidone in Patients Under Combined Treatment

  2016cited by this paper
• Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage: A Double-Blind Randomized Controlled Trial.

  2016cited by this paper
• Body mass index (BMI) but not body weight is associated with changes in the metabolism of risperidone; A pharmacokinetics-based hypothesis.

  2016cited by this paper
• Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype

  2016cited by this paper
• Risperidone-induced extrapyramidal side effects: is the need for anticholinergics the consequence of high plasma concentrations?

  2016cited by this paper
• Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients – thinking of clinically relevant CYP2D6 interactions

  2016cited by this paper
• Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics

  2013cited by this paper
• Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS).

  2012cited by this paper
• A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.

  2011cited by this paper
• AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011

  2011cited by this paper
• Effect of CYP2D6, CYP3A5, and MDR1 Genetic Polymorphisms on the Pharmacokinetics of Risperidone and Its Active Moiety

  2010cited by this paper
• Long-acting injectable risperidone and metabolic ratio: a possible index of clinical outcome in treatment-resistant schizophrenic patients

  2010cited by this paper
• Inconsistency in Risperidone Long‐Acting Injection Steady‐State Plasma Levels When Switching From Deltoid to Gluteal Administration

  2010cited by this paper
• Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance

  2009cited by this paper
• Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance

  2009cited by this paper
• Impact of CYP2D6 Genotype on Steady-State Serum Concentrations of Risperidone and 9-Hydroxyrisperidone in Patients Using Long-Acting Injectable Risperidone

  2009cited by this paper
• DNA Microarray Technology in the Clinical Environment: The AmpliChip CYP450 Test for CYP2D6 and CYP2C19 Genotyping

  2009cited by this paper
• A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: part I.

  2008cited by this paper
• Risperidone long-acting injection: a review of its long term safety and efficacy

  2008cited by this paper
• Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study.

  2007cited by this paper
• Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone

  2007cited by this paper
• A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder.

  2006cited by this paper
• Pharmacokinetic profile of long-acting injectable risperidone at steady-state: comparison with oral administration.

  2005cited by this paper
• Serum Concentrations of Risperidone and 9-Hydroxyrisperidone After Administration of the Long-Acting Injectable Form of Risperidone: Evidence From a Routine Therapeutic Drug Monitoring Service

  2005cited by this paper
• Determination of Five Commonly Used Antipsychotics in Human Serum by High Performance-Liquid Chromatography (HPLC) and Electrochemical Detection

  2005cited by this paper
• The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation.

  2005cited by this paper
• Therapeutic drug monitoring of patients on risperidone depot

  2005cited by this paper
• Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic.

  2003cited by this paper
• Glucuronidation enzymes, genes and psychiatry.

  2003cited by this paper
• Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes.

  2001cited by this paper
• Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test.

  1999cited by this paper
• Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors.

  1999cited by this paper
• Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials.

  1999cited by this paper
• Pharmacokinetics and drug interactions: update for new antipsychotics.

  1996cited by this paper
• Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man

  1995cited by this paper
• Pharmacologic approach to management of agitation associated with dementia.

  1994cited by this paper
• The pharmacokinetics of risperidone in humans: a summary.

  1994cited by this paper
• Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.

  1988cited by this paper

• Ultrafast solvent removal delivers high-loading of amorphous small-molecule drugs in polymeric microspheres with predictable in vivo performance.

  2026cites this paper
• Reassessing the Conduct of Patch Clamp Cardiac Ion Channel Assays to Improve Nonclinical Data Translation to Clinical ECG Changes and Proarrythmia Risk

  2025influential citation
• Pharmacokinetic characteristics of risperidone ISM for the treatment of schizophrenia

  2025cites this paper
• Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: Focus on antipsychotics

  2024cites this paper
• Unraveling the Influence of Age, IQ, Education, and Negative Symptoms on Neurocognitive Performance in Schizophrenia: A Conditional Inference Tree Analysis

  2023cites this paper
• Personalized switching from oral to long-acting injectable second-generation antipsychotics in schizophrenia treatment using pharmacokinetic considerations

  2023cites this paper
• Risperidone ISM as a New Option in the Clinical Management of Schizophrenia: A Narrative Review

  2022cites this paper
• Current and emerging long-acting antipsychotics for the treatment of schizophrenia

  2021cites this paper
• Pharmacokinetic Correlates of Once-Monthly Paliperidone Palmitate-Related Adverse Drug Reactions

  2021cites this paper
• A systematic review and pooled, patient‐level analysis of predictors of mortality in neuroleptic malignant syndrome

  2021cites this paper
• Long-Acting Risperidone Dual Control System: Preparation, Characterization and Evaluation In Vitro and In Vivo

  2021cites this paper
• The Relation between the Plasma Concentrations of Long-Acting Atypical Antipsychotics and Clinical Effectiveness in Patients Affected by Schizophrenia or Schizoaffective Disorder: A Comprehensive Overview.

  2021cites this paper
• A Machine Learning Model to Predict Risperidone Active Moiety Concentration Based on Initial Therapeutic Drug Monitoring

  2021cites this paper
• Effects of body weight, smoking status, and sex on plasma concentrations of once-monthly paliperidone palmitate

  2021cites this paper
• Pill or needle? Determinants of the preference for long-acting injection over oral treatment in people facing chronic illness.

  2020cites this paper
• CAFETERIA DIET ADMINISTERED FROM LACTATION TO ADULTHOOD PROMOTES A CHANGE IN RISPERIDONE SENSITIVITY ON ANXIETY, LOCOMOTION, MEMORY, AND SOCIAL INTERACTION OF WISTAR RATS.

  2020cites this paper
• Personalizing dosing of risperidone, paliperidone and clozapine using therapeutic drug monitoring and pharmacogenetics.

  2020cites this paper
• Revisited: Therapeutic and toxic blood concentrations of more than 1100 drugs and other xenobiotics

  2020cites this paper
• CYP2D6 pharmacogenetics and risperidone: reflections after 25 years of research.

  2020cites this paper
• Therapeutic Drug Monitoring of Long-Acting Injectable Antipsychotic Drugs.

  2020cites this paper
• Improving prediction of torsadogenic risk in the CiPA in silico model by appropriately accounting for clinical exposure.

  2019cites this paper
• Physiologically Based Pharmacokinetic Modelling to Describe the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone According to Cytochrome P450 2D6 Phenotypes

  2019cites this paper
• [Therapeutic drug monitoring of risperidone and its active metabolite 9-hydroxyrisperidone in the treatment of schizophrenia].

  2019cites this paper
• Concentration–Effect Relationships of Psychoactive Drugs and the Problem to Calculate Therapeutic Reference Ranges

  2019cites this paper
• Mood Stabilizers: Course and Duration of Therapy, Withdrawal Syndromes, and Resistance to Therapy

  2019cites this paper
• A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone

  2018cites this paper
• A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone

  2017cites this paper